ArticleThe World Allergy Organization journal2023
Global disparities in availability of epinephrine auto-injectors.
Article in The World Allergy Organization journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- The future of allergy and immunology care: A perspective on innovation, equity, and global collaboration from the WAO Junior Members Group.The World Allergy Organization journal · 2026Article
- Health inequities in pediatric anaphylaxis: A policy framework and call to action for equitable care from SIAIP allergy prevention commission.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Overview of allergic disease: Anaphylaxis - WAO White Book on Allergy 2026 - 2.11.The World Allergy Organization journal · 2026Review
- New Adrenaline Devices for Treating Anaphylaxis: Results of a Joint Survey From the European Anaphylaxis Registry and the Allergy-Vigilance Network.Clinical and translational allergy · 2026Article
- The forgotten billion: bridging the global allergy care chasm through scalable, equity-driven strategies.Frontiers in allergy · 2026Review
- Adult Food Allergy Is an Under-Recognized Health Problem in Northwestern Mexico: A Population-Based Cross-Sectional Survey.Epidemiologia (Basel, Switzerland) · 2025Article
- Global disparities in adrenaline access: A World Allergy Organization call for equity in anaphylaxis care.The World Allergy Organization journal · 2025Article
- Food allergy severity across the world: A World Allergy Organization international survey.The World Allergy Organization journal · 2025Article
- A World Allergy Organization (WAO) manifesto for the worldwide approval of biologic therapies for food allergy.The World Allergy Organization journal · 2025Article
- Recent Insights into the Epidemiology and Management of AnaphylaxisBalkan medical journal · 2025Review
- Food Allergy in Children in China.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- First-in-class intranasal epinephrine spray for anaphylaxis: Dose finding clinical study.The journal of allergy and clinical immunology. Global · 2025Article
- FDA approves neffy nasal spray for treatment of anaphylaxis in adult and pediatric patients.Annals of medicine and surgery (2012) · 2025Article
- Towards a common approach for managing food allergy and serious allergic reactions (anaphylaxis) at school. GAClinical and translational allergy · 2025Review
- Alternatives to Injectable Adrenaline for Treating Anaphylaxis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- Adrenaline Auto-Injectors for Preventing Fatal Anaphylaxis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- Changes in epinephrine dispensings and allergy hospitalisations in Sweden in the years following the removal of autoinjector co-payments.Frontiers in allergy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 20 institutions in 18 countries.
Funding
Abstract
Background: Anaphylaxis is the most severe clinical presentation of acute systemic allergic reactions and can cause death. Given the prevalence of anaphylaxis within healthcare systems, it is a high priority public health issue. However, management of anaphylaxis - both acute and preventative - varies by region. Methods: The World Allergy Organization (WAO) Anaphylaxis Committee and the WAO Junior Members Steering Group undertook a global online survey to evaluate local practice in the diagnosis and management of anaphylaxis across regions. Results: Responses were received from WAO members in 66 countries. While intramuscular epinephrine (adrenaline) is first-line treatment for anaphylaxis, some countries continue to recommend alternative routes in contrast to guidelines. Epinephrine auto-injector (EAI) devices, prescribed to individuals at ongoing risk of anaphylaxis in the community setting, are Conclusion: This survey provides a global snapshot view of the current management of anaphylaxis, and highlights key unmet needs including the global availability of epinephrine for self-injection as a key component of anaphylaxis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.